evipedia.ai
← Back

Oregano Oil for Health & Longevity

Evidence Review created on 11/06/2026 using AI4L / Opus 5.5

Also known as: Oil of Oregano, Oregano Essential Oil, Wild Oregano Oil, Origanum vulgare Essential Oil

Motivation

Oregano oil is a concentrated essential oil distilled from the leaves and flowering tops of the oregano plant (Origanum vulgare and close relatives). Unlike the culinary herb, the oil delivers large amounts of two aromatic compounds, carvacrol and thymol, which damage the outer walls of bacteria and fungi in laboratory tests. It is sold as liquid drops and softgels and promoted as a natural infection-fighting and immune supplement.

Oregano has a long history in Mediterranean folk medicine. Modern interest grew when food scientists tested the oil as a meat preservative and an antibiotic substitute in animal feed, and when people with gut infections and bacterial overgrowth began looking for plant-based alternatives to antibiotics. It is now one of the top-selling herbal supplements in the United States.

This review examines what human studies show about oregano oil for infections, blood fats and airway health, how strong that evidence is, and which side effects, drug interactions and product-quality problems are relevant for health-focused adults considering short courses or regular use.

Benefits - Risks - Protocol - Conclusion

This section lists high-level expert commentary and narrative reviews that discuss oregano oil or its antimicrobial use in depth.

  • Oil of Oregano - Scott Gavura

    A pharmacist’s skeptical appraisal contrasting abundant laboratory antimicrobial data for oil of oregano with the near-absence of controlled human trials and the wide range of marketed uses.

  • Essential Oils of Oregano: Biological Activity beyond Their Antimicrobial Properties - Leyva-López et al., 2017

    Narrative review of the chemical variability of oregano essential oils across species and their antioxidant, anti-inflammatory, antidiabetic and anticancer activity, drawn mostly from cell and animal studies.

Only two items qualify. The Life Extension oregano article is a short note on the culinary herb, not an in-depth discussion of the oil. Chris Kresser’s Revolution Health Radio SIBO episode on SIBO (small intestinal bacterial overgrowth, excess bacteria in the small bowel) mentions oregano oil in a single sentence, among other herbal antimicrobials. Rhonda Patrick mentions oregano oil only briefly, as one of several antimicrobials, in members-only Q&A episodes (FoundMyFitness Q&A #9; FoundMyFitness Q&A #26). Peter Attia, Andrew Huberman and Lifespan.io have no content discussing oregano oil: site and web searches found none.

Grokipedia

Oil of Oregano

Covers the botanical sources, carvacrol and thymol content, traditional uses and marketed indications of the oil, noting that human clinical evidence varies in strength and that irritation and interactions warrant caution.

Examine

Oregano benefits, dosage, and side effects

States that human evidence for oregano supplementation is lacking, that the only oral oil trial used 600 mg daily, and that this lone positive intestinal-infection study was funded by an oregano oil manufacturer.

ConsumerLab

8 Supplements That May Help Treat Peptic Ulcers – And Some to Avoid

ConsumerLab’s oregano oil section reports carvacrol testing of Amazon products, run by competitor NOW Foods, in which about half fell short or contained almost none, and gives product picks and safety notes.

Systematic Reviews

This section lists systematic reviews and meta-analyses covering oregano, its genus or its main active compound carvacrol.

No systematic review or meta-analysis of oregano oil’s adverse effects, drug interactions or safety exists; the risk side is unrepresented.

Mechanism of Action

Oregano oil is dominated by phenolic monoterpenes (small aromatic plant compounds), chiefly carvacrol with smaller amounts of thymol, plus their precursors p-cymene and γ-terpinene; the mix varies widely by species and harvest (narrative review, Leyva-López 2017).

  • Membrane disruption: carvacrol’s hydroxyl group embeds in bacterial and fungal membranes, leaking ions and ATP (adenosine triphosphate, the cell’s energy currency) and weakening biofilms (protective microbial slime layers) (review, Sharifi-Rad 2018).
  • Ion channels: carvacrol activates TRPV3 and TRPA1 (heat- and irritant-sensing channels on nerve endings), producing the oil’s warming burn (Xu 2006), and blocks TRPM7 (a magnesium channel involved in cell survival) (systematic review, Zamanian 2021).
  • Inflammation: in animals carvacrol lowers inflammatory signalling and oxidative damage in injured lungs (systematic review, de Carvalho 2020).
  • Pharmacology: carvacrol is non-selective, hitting many targets. Its human half-life, tissue distribution and bioavailability are uncharacterized. Its close chemical relative thymol is absorbed and conjugated to sulfate and glucuronide (water-soluble tags added for excretion); thymol sulfate’s elimination half-life is about 10 hours (Kohlert 2002). Oregano extract activates PXR and AhR (receptors that switch on drug-clearing genes) and induces CYP3A4 and CYP1A2 (liver enzymes that break down many drugs) in cell assays (Haron 2023).
  • Competing view: most carvacrol is absorbed or diluted in the upper gut, so concentrations reaching distant gut segments or tissues may fall below laboratory inhibitory levels; local irritation and anti-inflammatory effects, not microbial killing, may explain clinical observations.

Historical Context & Evolution

Oregano was originally a culinary and folk-medicine herb. Classical Greek physicians, including Dioscorides, described it for digestive, respiratory and skin complaints, and Mediterranean folk medicine used infusions for coughs and indigestion. In Uruguay, oregano also appears in herbal mixtures taken to induce abortion (Ciganda 2003).

The concentrated oil entered modern use through the food and livestock industries, where carvacrol-rich oils preserve meat and, after antibiotic growth promoters were restricted, became a natural feed additive for disease control (review, Cui 2024). In the late 1990s, popular books and North American supplement makers promoted “oil of wild oregano” as a broad-spectrum antimicrobial. The first human report, an uncontrolled 14-patient parasite study that reported parasite clearance in most patients, came from authors affiliated with a supplement manufacturer (Force 2000).

Interest grew with antibiotic resistance and with integrative gastroenterology clinics testing herbal antimicrobial blends for small intestinal bacterial overgrowth, with clearance rates similar to an antibiotic (Chedid 2014). An Iranian group then ran small randomized trials of purified carvacrol in asthma and chemical lung injury, reporting improved lung function (Alavinezhad 2018).

Opinion has moved on two fronts. Laboratory evidence of antimicrobial and anti-inflammatory activity has accumulated steadily, while clinical trials of the oil itself remain few, small and partly industry-linked. A new concern appeared when cell assays showed oregano extract switching on drug-metabolizing enzymes as strongly as St. John’s wort (Haron 2023), prompting a federally funded human interaction trial (NCT06693960) that has not yet reported.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: no clinical outcome or validated surrogate has been replicated by independent groups in controlled trials of oregano oil; human data are single small trials, uncontrolled series and trials of related forms.

Medium 🟩 🟩

No benefit reaches Medium: the only randomized trial of oral oregano oil itself (lipids) is tiny and its main finding is an HDL rise, a randomized trial of oregano extract found no lipid change, and every other controlled trial tested purified carvacrol, leaf extracts or multi-herb blends, which count as indirect evidence.

Low 🟩

Blood Lipids ⚠️ Conflicted

Oral Origanum essential oils raised HDL in a 14-day, four-arm trial of 34 athletes (Maral 2022); an oregano distillate (indirect form) lowered LDL in adults with high cholesterol (Ozdemir 2008). A randomized controlled trial (RCT) of oregano-extract juice found no lipid change (Nurmi 2006). Net: a small, inconsistent signal.

Magnitude: In the one Origanum trial pooled by a meta-analysis (distillate, not oil), LDL fell 9.6 mg/dL (95% CI, the confidence interval or plausible range, 4.4 to 14.8) and HDL rose 3.5 mg/dL (95% CI 1.6 to 5.5) more than in controls (Hassanpour 2024).

Gastrointestinal Infections

Emulsified oil, 600 mg/day for 6 weeks, cleared intestinal parasites in most of 14 adults in an uncontrolled study by manufacturer-affiliated authors (Force 2000). Multi-herb blends containing oregano (indirect) matched rifaximin (a gut antibiotic) for SIBO in a non-randomized clinic comparison (Chedid 2014).

Magnitude: Negative breath test after 4 weeks in 46% (17/37) on herbal blends vs 34% (23/67) on rifaximin, OR (odds ratio, how many times likelier the outcome was with herbs) 1.85 (95% CI 0.77 to 4.41), not significant; parasites cleared in 13 of 16 infections with oil (no control group).

Surgical Wound Contamination

In a randomized double-blind trial of 40 patients after skin excision, 3% oregano extract ointment reduced bacterial contamination and infections versus petrolatum, with equivalent overall scar appearance (Ragi 2011). Evidence is indirect: a topical leaf extract, not ingested oil.

Magnitude: Staphylococcus aureus-positive wound cultures in 19% with oregano ointment vs 41% with petrolatum; cellulitis (spreading skin infection) in 1 vs 3 patients; no CI reported.

Airway Symptoms and Lung Function

Carvacrol, 1.2 mg/kg/day for 2 months, improved lung-function tests and symptoms versus placebo in a small asthma RCT (Alavinezhad 2018) and lung volume and peak airflow in sulfur-mustard lung injury (chemical-weapon lung damage) (Khazdair 2018). All come from one group; carvacrol alone is indirect evidence for the oil.

Magnitude: Direction only: lung-function values (both trials) and asthma symptom scores improved over 2 months with carvacrol and did not change with placebo; the trial reports give p-values (the probability that a result arose by chance) but no between-group effect-size figure.

Upper Respiratory Symptom Relief

A five-oil throat spray including Origanum syriacum (indirect: oils tested together) relieved sore throat, hoarseness or cough more than placebo at 20 minutes in 60 patients, but not after 3 days (Ben-Arye 2011). The abstract prints day-3 P = .042; the results section gives P = .42, followed here.

Magnitude: Improvement of at least one symptom grade at 20 minutes in 73.1% (19/26) of spray users vs 41.2% (14/34) of placebo users (P = .019); at day 3, 72.0% vs 58.8% (P = .42); no CI reported.

Bacterial Vaginosis

A vaginal tablet of oregano and lemon balm extracts matched metronidazole (an antibiotic) for bacterial vaginosis (vaginal bacterial imbalance) in a 130-woman randomized non-inferiority trial (designed to show it is not worse) co-authored by a herbal manufacturer (Mesdaghinia 2025). Under half completed 10 days; extracts and vaginal route are indirect.

Magnitude: Mean total symptom-score reduction at day 10 was 6.58 with the herbal tablet vs 7.35 with metronidazole, not significantly different; no CI reported.

Speculative 🟨

Antifungal Activity

Origanum essential oils inhibit Candida, Aspergillus and Penicillium fungi in laboratory MIC assays, with carvacrol and thymol as key actives (systematic review, Mezzomo 2025). The basis is in-vitro data only.

Anticancer Activity

Carvacrol and thymol (compounds, not the oil) trigger apoptosis (programmed cell death) and block PI3K/AKT/mTOR (cell-growth signalling) in 77 cell and animal studies (systematic review, Sampaio 2021). No human data exist; the basis is mechanistic.

Neuroprotection

Carvacrol alone (not the oil) reduced oxidative stress, inflammation and neuron loss in animal models of stroke, brain injury, Parkinson’s and Alzheimer’s disease, partly via TRPM7 blockade (systematic review, Zamanian 2021). Animal data only.

Oxidative Stress and Exercise Muscle Damage ⚠️ Conflicted

Dried oregano leaf (500 mg, indirect form) after combat testing lowered CK (creatine kinase, a muscle-damage marker) in 24 soldiers (Shirvani 2022); extract juice left lipid oxidation unchanged (Nurmi 2006). Net: unvalidated markers, inconsistent results.

Benefit-Modifying Factors

  • Genetic polymorphisms: No study has examined gene variants. Carvacrol and thymol are cleared by conjugation enzymes (UGT, which attach glucuronide, and SULT, which attach sulfate); common variants in these could plausibly alter exposure, but this is untested.
  • Baseline biomarkers: LDL fell in people with raised LDL (Ozdemir 2008), not in healthy men with normal cholesterol (Nurmi 2006); healthy athletes showed an HDL rise (Maral 2022). Antimicrobial benefit presupposes a documented infection, such as a positive breath or stool test.
  • Sex: No sex comparisons exist. Lipid, exercise and parasite data come mainly from men or mixed groups; the bacterial vaginosis data are from women only.
  • Pre-existing conditions: Signals come from people with parasites, SIBO, asthma, chemical lung injury or high cholesterol. Healthy adults without these conditions have no demonstrated benefit beyond culinary use.
  • Age: Trials enrolled mostly adults under 65. Older adults, who more often take multiple medications, have no efficacy data and face the enzyme-induction uncertainty described under risks.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: adverse events of oregano oil have not been tracked in controlled trials by more than one independent group; human safety data come from small trials, one clinic comparison and case reports.

Medium 🟥 🟥

No risk reaches Medium: no controlled trial or comparative observational study has shown an excess adverse-event rate for oregano oil over placebo or a comparator.

Low 🟥

Gastrointestinal Irritation

Concentrated oil can cause heartburn, a burning “heated sensation”, nausea, cramping and diarrhea, likely through irritant-channel activation in the gut. Evidence is uncontrolled: product labels and a clinic comparison of herbal blends (indirect) in which diarrhea was rare (Chedid 2014).

Magnitude: Diarrhea in 1 of 37 herbal-blend users vs 2 of 67 rifaximin users in a non-randomized comparison, not significantly different (P = .22).

Mucosal and Skin Irritation

Undiluted oil burns the mouth, throat and skin because carvacrol activates irritant receptors (Xu 2006). Applied to the human tongue, carvacrol produced burning and stinging that faded with repeated application (Klein 2013). Evidence is indirect: purified carvacrol, not the oil. Severity depends on dilution.

Magnitude: Not quantified in available studies. Human data are sensory-rating experiments; no study has measured how often oral or topical use causes clinical irritation.

Allergic Reactions

Oregano is a Lamiaceae (mint-family) herb; people sensitized to basil, mint, sage, thyme or lavender may cross-react. Case reports describe systemic reactions after eating oregano and thyme (Benito 1996) and angioedema (deep swelling of skin and lips) confirmed by oral oregano challenge (Yazıcı 2018). Both involve the culinary herb (indirect).

Magnitude: Not quantified in available studies. Only case reports exist; no study has measured the frequency of oregano allergy.

Pregnancy Loss

Oregano is a traditional ingredient of abortion-inducing herbal mixtures. Uruguayan poison-centre records linked a commercial mixture of oregano, pennyroyal and two other herbs to abortion, organ failure and one death (Ciganda 2003). Evidence is indirect (multi-herb product); oregano’s own contribution is unknown.

Magnitude: Not quantified in available studies. Only poison-centre case data on a multi-herb product exist; no study has examined oregano oil in pregnancy.

Liver Injury

A US network collecting cases of drug- and supplement-induced liver injury listed an oregano single-ingredient product among supplements implicated in liver injury in 2004–2013 (Navarro 2014). Causality was judged by expert opinion; product form and dose were not reported. Evidence is registry case data only.

Magnitude: Not quantified in available studies. Only registry case data exist; no study has measured how often oregano products injure the liver.

Red-Cell and Iron Shifts

In a phase I (first safety-stage) study of 30 healthy adults, one month of purified carvacrol at 2 mg/kg/day lowered serum iron, red-cell count and hematocrit (red-cell share of blood volume) from baseline, all staying within normal ranges (Ghorani 2021). Carvacrol alone is indirect evidence for the oil.

Magnitude: Direction only: decreases from baseline, all within normal ranges (no control group; the two dose groups differed only in lactate dehydrogenase (an energy-metabolism enzyme released by damaged cells) and three red-cell size and hemoglobin-content indices); the report gives no adverse-event rate.

Bleeding Tendency

Carvacrol mildly inhibited platelet aggregation (clumping of clotting cells) in laboratory assays (Karkabounas 2006). In healthy adults, carvacrol lengthened prothrombin time (a clotting test) within normal ranges (Ghorani 2021); oregano and occasional verbena tea raised an anticoagulant (anti-clotting drug) user’s INR (clotting test) (Beghriche 2025). Indirect evidence: compound or herb.

Magnitude: In one case report, INR rose to 6.42 against a target of 2–3 during daily oregano tea with occasional verbena and fell after both the tea and acenocoumarol were paused (no control group); no study has measured a bleeding-event rate.

Speculative 🟨

Drug Interactions via Enzyme Induction

An alcohol-water oregano extract (not the oil), like St. John’s wort, raised CYP3A4 and CYP1A2 activity by over 50% in cell assays (Haron 2023). This could lower many drugs’ blood levels; human confirmation is pending.

White-Cell Suppression at High Doses

In rats with chemical liver injury, oregano oil at 60 mg/kg for 2 weeks lowered white-cell and lymphocyte (immune cell) counts (Suljević 2024). The basis is a single animal study.

Risk-Modifying Factors

  • Genetic polymorphisms: No pharmacogenetic data exist. People who are poor metabolizers through CYP2C19 (an enzyme clearing omeprazole and clopidogrel) or CYP2D6 (an enzyme clearing many antidepressants) may react differently to enzyme induction, untested for oregano.
  • Baseline biomarkers: Low ferritin (iron stores) or borderline hemoglobin makes the small carvacrol-related iron and red-cell decreases more relevant (Ghorani 2021). Abnormal clotting tests add weight to the bleeding concern.
  • Sex: Women who are or may become pregnant face the abortion-related concern (Ciganda 2003). Oral contraceptives are CYP3A4 substrates and could, in theory, lose efficacy through enzyme induction.
  • Pre-existing conditions: Reflux, peptic ulcer or inflammatory bowel disease raise susceptibility to gut irritation. Allergy to mint-family herbs raises allergy risk (Benito 1996). Bleeding disorders amplify the platelet concern.
  • Age: Adults over 65 take more CYP-cleared drugs, raising interaction exposure. Undiluted essential oil is a poisoning hazard for children in the household.

Key Interactions & Contraindications

Documented interactions:

  • Iron supplements (ferrous sulfate, iron bisglycinate) and dietary iron: oregano herb (not the oil) added to a test meal inhibited iron absorption in a human study (Brune 1989); carvacrol lowered serum iron (Ghorani 2021). Consequence: reduced iron status. Mitigation: doses separated by 2 hours.
  • Warfarin-type anticoagulants (vitamin K-blocking anti-clotting drugs: warfarin, acenocoumarol): in a case report, daily oregano infusion (herb, not the oil), with occasional verbena, raised an acenocoumarol user’s INR to 6.42, normalizing after stopping (Beghriche 2025). Consequence: bleeding risk. Mitigation: INR checked within 2 weeks.

Both documented items involve the culinary herb; no human interaction or pharmacokinetic (absorption and clearance) study, product label or regulator documents an interaction with oregano oil itself; the first human drug-interaction trial (NCT06693960) has not reported.

Theoretical interactions (inferred from mechanism, not studied in humans):

  • CYP3A4 substrates (tacrolimus, cyclosporine, midazolam, oral contraceptives, simvastatin): inferred from CYP3A4 induction in cell assays (Haron 2023); lower drug levels could cause transplant rejection or contraceptive failure. Mitigation: avoiding narrow-margin drugs, or checking drug levels if combined.
  • CYP1A2 substrates (theophylline, clozapine, tizanidine, caffeine): inferred from CYP1A2 induction (Haron 2023); reduced drug effect, or toxicity when oregano is stopped. Mitigation: theophylline or clozapine levels checked when starting or stopping.
  • Direct oral anticoagulants (anti-clotting drugs that block one clotting factor directly: apixaban, rivaroxaban) and antiplatelet drugs (platelet-clumping blockers: clopidogrel, aspirin): inferred from carvacrol’s antiplatelet action in laboratory assays (Karkabounas 2006); additive bleeding risk. Mitigation: watching for bleeding; pausing 2 weeks before procedures.
  • Glucose-lowering drugs (metformin, sulfonylureas, which push the pancreas to release insulin, such as glipizide, insulin): inferred from oregano leaf extract’s glucose-lowering activity in cell and enzyme assays (Yu 2021); additive low blood sugar. Mitigation: glucose monitoring during the first weeks.
  • Lithium: inferred from oregano’s purported diuretic (water-excreting) effect, which could reduce lithium excretion; raised lithium levels and toxicity. Mitigation: lithium levels checked when starting or stopping.
  • Over-the-counter drugs (omeprazole, dextromethorphan, ibuprofen, naproxen): reduced omeprazole and dextromethorphan levels, weakening acid suppression and cough relief, inferred from enzyme induction; additive stomach irritation with NSAIDs (non-steroidal anti-inflammatory drugs). Mitigation: dosing with food and not stacking with NSAIDs.
  • Supplements with additive effects (fish oil, ginkgo, garlic, vitamin E; berberine; St. John’s wort): additive antiplatelet effect raising bleeding risk, additive glucose lowering causing low blood sugar, or stacked enzyme induction reducing drug effect. Mitigation: not stacking several such supplements during a course.
  • Probiotics and other antimicrobial herbs (thyme oil, berberine, allicin): inferred from broad antimicrobial action; reduced probiotic viability, or additive gut irritation and microbiome disruption. Mitigation: probiotics separated by 2–3 hours.

Populations who should avoid Oregano Oil:

  • Pregnancy and breastfeeding: human harm documented only for a multi-herb abortifacient (abortion-inducing preparation) containing oregano (Ciganda 2003); risk from oregano oil itself is inferred from this traditional abortifacient use; breastfeeding avoidance is inferred from possible carvacrol transfer into milk. No oregano-only human data.
  • Known allergy to mint-family herbs (oregano, thyme, sage, mint, basil, lavender, marjoram): human systemic allergic reactions and cross-sensitivity documented in case reports (Benito 1996).
  • Organ-transplant recipients on tacrolimus or cyclosporine: inferred from CYP3A4 induction in cell assays (Haron 2023); no human data.
  • Scheduled surgery within 2 weeks or bleeding disorders: inferred from laboratory antiplatelet activity (Karkabounas 2006); no human data.
  • Young children (undiluted essential oil): inferred from carvacrol’s irritant action on mucosa (Xu 2006); no pediatric dosing or safety data.

Risk Mitigation Strategies

Doses and timings below follow common practice unless cited.

  • Dilution and food: softgels pre-diluted in olive oil, or drops mixed into water, taken with meals reduce heartburn, nausea and mucosal burning.
  • Enteric-coated softgels: coating releases oil past the stomach, reducing stomach pain and “heated sensations” reported with uncoated products.
  • Time-limited courses: oral courses of 2–6 weeks, matching the 4–6-week durations studied (Force 2000; Chedid 2014), limit microbiome disruption and unknown long-term effects.
  • Patch test before topical use: diluted oil on a small skin area for 24 hours reveals irritation or allergy before wider application.
  • Medication review: a pharmacist screen of all CYP3A4- and CYP1A2-cleared drugs before starting guards against loss of drug effect from enzyme induction.
  • Pause before surgery: stopping 2 weeks before planned surgery or dental extraction reduces the bleeding risk.
  • Iron status checks: ferritin and hemoglobin before and after courses longer than 4 weeks detect the iron and red-cell decreases seen with carvacrol (Ghorani 2021).
  • Stopping at allergy signs: hives, lip or tongue swelling or breathing difficulty, the allergic reactions documented in case reports, are the point to stop use and obtain urgent medical care.
  • Stopping at liver warning signs: jaundice (yellowing of skin and eyes), dark urine or upper-right abdominal pain are the point to stop use and obtain liver tests, given registry cases of supplement-related liver injury (Navarro 2014).
  • Storage away from children: child-resistant containers for concentrated essential oil prevent accidental ingestion and mucosal burns.

Therapeutic Protocol

Timing, cycling and titration parameters without a citation reflect common practice.

  • Emulsified oil (integrative approach): 600 mg/day emulsified oregano oil for 6 weeks in the parasite study (Force 2000), the one oral oil dose cited on the Examine oregano page.
  • Carvacrol-standardized dosing: 123 mg carvacrol/day for 15 days, then 62 mg for 30 days, split twice daily, from a savory–oregano–thyme blend in a company-linked case series (Nikolić 2023); ConsumerLab builds its product dosing on this range (ConsumerLab peptic ulcer article).
  • Research softgel dose: 180 mg oil of oregano softgel daily for 5 days in the ongoing interaction trial (NCT06693960).
  • Purified carvacrol: 1.2 mg/kg/day in three doses for 2 months (Alavinezhad 2018); 1–2 mg/kg/day was tolerated for one month (Ghorani 2021).
  • SIBO, integrative versus conventional: herbal blends for 4 weeks, popularized by an integrative Johns Hopkins clinic, vs rifaximin 1,200 mg/day for 4 weeks (Chedid 2014). Chris Kresser reserves oregano oil for practitioner-supervised use (Revolution Health Radio SIBO episode).
  • Topical use: 3% oregano extract ointment on post-surgical wounds (Ragi 2011); essential oil for skin is diluted in a carrier oil.
  • Time of day: with meals for tolerance (product labels); Helicobacter pylori (ulcer-causing stomach bacterium) series authors suggest 30 minutes before meals, from laboratory data (Nikolić 2023). Sources differ; morning and midday dosing avoid evening heartburn.
  • Half-life: carvacrol’s human half-life is unknown; thymol sulfate’s is about 10 hours (Kohlert 2002), supporting once- to twice-daily dosing.
  • Single vs split doses: split dosing (two to three times daily) was used in the carvacrol (Alavinezhad 2018) and H. pylori (Nikolić 2023) studies and improves gut tolerance.
  • Genetic polymorphisms: no variant-guided dosing exists; people with known CYP2C19 or CYP2D6 poor-metabolizer status on affected drugs have the most to lose from enzyme induction.
  • Sex: no sex-specific dosing data exist; pregnancy is listed among populations who should avoid oregano oil.
  • Age: trials enrolled adults up to about 64; for older adults on several medications, lower starting doses and a medication review are common practice.
  • Baseline biomarkers: a confirmed target (positive breath test, stool parasite test, raised LDL) before a course allows response to be judged.
  • Pre-existing conditions: reflux or ulcer disease favors enteric-coated, lower doses; asthma data come from carvacrol at 1.2 mg/kg/day (Alavinezhad 2018).

Discontinuation & Cycling

  • Short-term, not lifelong: all human data cover 14 days to 3 months; oregano oil is used as a defined course for a documented problem, not as a daily longevity supplement.
  • Withdrawal effects: none reported. Stopping may raise levels of drugs previously lowered by enzyme induction, relevant for theophylline, clozapine or tacrolimus users.
  • Tapering: no taper is needed for oregano oil itself; drug levels affected by induction are rechecked 1–2 weeks after stopping.
  • Cycling: no evidence supports cycling for efficacy. Practitioners separate courses by several weeks to allow microbiome recovery; a positive retest after 4–6 weeks prompts another course or a conventional antibiotic.

Sourcing and Quality

  • Carvacrol content: quality oils state carvacrol percentage (typically 55–85%). In testing by competitor NOW Foods, 21 of 35 Amazon products missed their carvacrol claim and 6 had none (NOW Amazon test report; ConsumerLab peptic ulcer article).
  • Species and adulteration: Origanum vulgare subsp. hirtum and Origanum onites yield high-carvacrol oil; cheaper products may substitute thyme, Spanish oregano (Thymbra capitata) or synthetic carvacrol. Labels naming the botanical species and origin indicate traceable sourcing.
  • Formulation: supplements dilute oil in olive or coconut oil, often about 1:4. Pure essential oils labelled for aromatherapy are not intended for ingestion.
  • Third-party testing: USP (United States Pharmacopeia) or NSF (NSF International) certification, or a batch certificate of analysis reporting carvacrol by gas chromatography; indicates verified content; ConsumerLab has not tested oregano oil itself.
  • Brands: ConsumerLab’s picks, based on NOW’s testing, are Carlyle Organic Oil of Oregano (liquid), Horbaach Oil of Oregano softgels and NOW Oregano Oil enteric-coated softgels.

Practical Considerations

  • Time to effect: gut symptoms in the H. pylori series (an oil blend including oregano) eased within 10 days (Nikolić 2023); SIBO and parasite courses lasted 4–6 weeks (Chedid 2014; Force 2000); lung-function changes with carvacrol appeared after 1–2 months (Alavinezhad 2018).
  • Common pitfalls: taking undiluted oil, using it continuously as a daily “immune” supplement, buying unverified products with little carvacrol, and overlooking drug interactions.
  • Regulatory status: in the United States oregano oil is a dietary supplement, not FDA-approved before marketing (FDA dietary supplement Q&A); Origanum essential oil is generally recognized as safe as a food flavoring (FDA, 21 CFR 182.20), not as a medicine.
  • Cost and payer incentives: oregano oil courses cost a few dollars, far less than rifaximin; payers have a financial incentive favoring cheaper options, while unpatentable herbs attract little trial funding, a structural bias toward sparse evidence.
  • Self-diagnosis: gut symptoms attributed to “parasites” or “overgrowth” often have other causes; testing before treatment avoids masking conditions that need medical care.

Interaction with Foundational Habits

  • Sleep: none known. No study has measured sleep; evening doses can provoke reflux that disturbs sleep, so morning or midday dosing is common practice.
  • Nutrition: direct. Food reduces gut irritation; culinary oregano in a Mediterranean diet supplies small amounts of the same compounds. Carvacrol lowered serum iron in one study (Ghorani 2021), so iron-rich meals or supplements are separated from doses.
  • Exercise: indirect, possibly potentiating recovery. Dried oregano lowered muscle-damage markers after intense military exercise (Shirvani 2022), and oregano oils raised HDL in athletes (Maral 2022); no data on training adaptation.
  • Stress management: none known. No study has measured cortisol or the stress response to oregano oil, and no mechanism links carvacrol to stress hormones; no timing adjustments around stress practices are needed.

Monitoring Protocol & Defining Success

Before starting, baseline testing confirms that a target problem exists and records safety values. This means a lactulose breath test or stool parasite test for suspected gut infection, a fasting lipid panel when lipids are the aim, and a complete blood count with ferritin. People on CYP3A4- or CYP1A2-cleared drugs with narrow safety margins add a drug level, and warfarin users an INR.

Ongoing monitoring follows a cadence of a symptom check at 2 weeks, retesting of the target problem 4–6 weeks after the course ends, and repeat blood count and ferritin at the end of any course longer than 4 weeks. Drug levels or INR are rechecked 1–2 weeks after starting and again after stopping. Success means a negative retest, improved lipids, or symptom relief without adverse effects.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Hemoglobin Men 13.5–17.5 g/dL; women 12.0–15.5 g/dL (standard reference range) Safety check: carvacrol lowered red-cell indices Part of a complete blood count; no fasting needed (Ghorani 2021)
Ferritin Men 24–336 ng/mL; women 11–307 ng/mL (standard reference range) Safety check: carvacrol lowered serum iron Ferritin reflects iron stores; inflammation raises it falsely; pair with serum iron
LDL cholesterol No established target; track change from own baseline Expected to change: lipid signal in Origanum trials Fasting lipid panel; morning draw; track change from own baseline; recheck after 8–12 weeks (Ozdemir 2008)
HDL cholesterol No established target; track change from own baseline Expected to change: HDL rose in oil and distillate trials Same fasting panel as LDL; track change from own baseline (Maral 2022)
Lactulose breath test No established target; track whether a positive test turns negative Expected to change: defines SIBO response Requires a 12-hour fast and low-fermentation diet the day before; 4-week herbal courses studied (Chedid 2014)
Stool parasite test No established target; track whether a positive test turns negative Expected to change: defines parasite response Retest 4–6 weeks after the course; clearance studied after 6 weeks of 600 mg/day oil (Force 2000)
INR (warfarin-type anticoagulant users only) No established target for this interaction; track change from own stable INR Safety check: oregano tea raised INR on acenocoumarol Recheck 1–2 weeks after starting and after stopping; INR reached 6.42 in a case report (Beghriche 2025)

Qualitative markers to track:

  • Digestive comfort: bloating, gas, stool form and abdominal pain
  • Heartburn or “heated sensation” after doses
  • Respiratory symptoms: cough, wheeze, sore throat
  • Skin reactions at application sites, or hives
  • Energy and exercise recovery

Emerging Research

  • Oregano–drug interaction trial (NCT06693960): early phase 1, 16 healthy adults; 180 mg oil softgel for 5 days with a five-drug probe cocktail; primary endpoint midazolam AUC (area under the curve, total exposure) ratio; recruiting, completion estimated January 2027. A positive result confirms clinically relevant interactions; a null result largely removes the main theoretical risk.
  • Oregano and basil leaves after unstable angina (chest pain at rest from narrowed heart arteries) (NCT07123181): 70 patients in Iran; inflammatory markers and lipids. Registered completion (October 22, 2026) has passed; the record still says recruiting, with no results posted. Positive results would support the lipid item; null results would weaken it.
  • Carvacrol in COVID-19 (NCT05445089): 600 patients in Venezuela, placebo-controlled, mortality and inflammatory endpoints; completed December 2020, no results posted; led by the tested product’s (Carvativir) developer. A non-PubMed journal abstract reports median recovery of 7 vs 14 days and 15-day mortality of 0% vs 4% (Ojeda 2022), with internally inconsistent statistics.
  • Oregano mouthwash for halitosis (persistent unpleasant breath odor) (NCT04779502): 54 participants comparing an oregano oil mouthwash with chlorhexidine and water; completed November 2020; the registry summary claims reduced odor scores, but no results are posted.
  • Gut antimicrobial trials: randomized trials of oregano oil alone against rifaximin for SIBO are needed; current support rests on a retrospective blend comparison (Chedid 2014) and an uncontrolled company case series (Nikolić 2023).
  • Weakening evidence: a well-powered null lipid or antioxidant trial would extend the existing null RCT (Nurmi 2006); evidence that oregano oil disrupts beneficial gut bacteria would shift risk-benefit.
  • Human pharmacokinetics: carvacrol’s absorption and half-life in people remain uncharacterized; only thymol has been measured (Kohlert 2002). Data would show whether tissue levels reach laboratory-active concentrations.

Conclusion

Oregano oil is a concentrated plant oil whose main compounds kill bacteria and fungi in the laboratory and irritate nerve endings, which explains its warming burn. For health-focused adults, its appeal is as a plant-based option for gut infections, bacterial overgrowth and respiratory complaints.

The human evidence is thin. Every benefit rests on small, short or indirect studies: tests of single compounds, leaf extracts, ointments or multi-herb blends, a small parasite study without a comparison group, and one tiny trial of the oil itself on blood fats, while a trial of an oregano extract found no change. Laboratory work on cancer, brain protection and fungal infection has not been tested in people. Several key studies were run or funded by companies that sell oregano products, and the main product test was carried out by a competing supplement maker.

The risks are mostly mild and local: stomach irritation, burning of the mouth and skin, and uncommon allergy in people sensitive to mint-family herbs. Two concerns stand out. Oregano has a history in herbal mixtures used to end pregnancies, and cell studies suggest it may speed the breakdown of many medications, a possibility a human study is now testing. Product quality is uneven, with many products containing little of the active compound.

Taken together, oregano oil is a plausible short-course tool with real but unproven promise and no demonstrated role as a daily longevity supplement.

Top - Benefits - Risks - Protocol